Titan Pharmaceuticals announced this morning that its Parkinson's drug Spheramine failed to hit primary and secondary endpoints in a Phase IIb trial for moderate to advanced Parkinson's disease. Researchers said there was no significant difference in response between the Spheramine group and the placebo arm. Titan says that it will analyze the data gathered on the 71 patients in the study.
Bayer, for its part, swiftly washed its hands of the program. "We will not develop (this drug) further and we will not invest in it further," said Bayer spokesman Jost Reinhard.